MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY


MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY

Moberg Derma AB (STO: MOB) has entered into a distribution agreement with
Menarini Group for Emtrix® – for discolored and damaged nails caused by nail
fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC
Division is granted exclusive rights to market and sell Emtrix® in Italy under
the trademark YouDerm Emtrix®.

“The agreement is part of our international commercialization of Emtrix®. As the
leading Italian pharmaceutical group, ranked 34th in the world, Menarini is well
positioned to make Emtrix® a success in Italy. Emtrix® will now be marketed in
all large markets in Europe, in US and Australia”, says Peter Wolpert, President
and CEO of Moberg Derma.

About Emtrix® and nail disease
Emtrix® is a topical treatment used to treat nail disease. Launched in the
Nordic region in autumn 2010, it quickly became market leader. Emtrix® is a
prescription free, over-the-counter product sold under the name Nalox™ in
certain markets and under the name Kerasal® Nail in the U.S. Safety and efficacy
have been demonstrated in several clinical studies including more than 600
patients. Emtrix® has a unique and rapid mechanism of action which brings
visible improvements within 2-4 weeks of treatment. Nail fungus is the most
common nail disease and afflicts approximately 10% of the general population and
increasing with age. The estimated global market potential exceeds USD 1
billion. The untapped potential is significant since many patients remain
untreated. It is generally recognized that there is a need for new efficacious
and safe topical treatments.

About this information
Moberg Derma discloses the information provided herein pursuant to the
Securities Markets Act and/or the Financial Instruments Trading Act. The
information was submitted for publication at 08:00 am (CET) on December 9th,
2011.

For further information, please contact:
Peter Wolpert, President and CEO
Telephone: 46 8 522 307 00
Mobile: 46 735 71 35
E-mail: peter.wolpert@mobergderma.se

Magnus Persson, IR
Mobile: 46 73-355 26 01
E-mail: magnus.persson@mobergderma.se

Attachments